BiovelocITA
Overview
BiovelocITA is the first biotech accelerator in Italy, founded in 2015 by Silvano Spinelli, Gabriella Camboni, and Sofinnova Partners. It operates as a company builder, providing financial resources and hands-on management to accelerate early-stage, innovative biotech projects and transform them into successful companies. The firm supports projects from proof-of-concept to clinical phases, focusing on areas like rare genetic diseases, diabetes, and oncology.
Portfolio Companies
2
Website
biovelocita.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Enthera | Jul 2018 | Seed | Co-investor |
| Alia Therapeutics | Jun 2021 | Seed | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is BiovelocITA based?
BiovelocITA is headquartered in Milan, Lombardy, Italy.
When was BiovelocITA founded?
Founding year information for BiovelocITA is not publicly available.
How many portfolio companies does BiovelocITA have?
BiovelocITA has 2 portfolio companies in Caplight's dataset.
What are some companies in BiovelocITA's portfolio?
Portfolio companies visible on Caplight include Enthera, Alia Therapeutics.
What was BiovelocITA's most recent investment shown here?
BiovelocITA's most recent investment in this portfolio sample was in Alia Therapeutics in 2021.
What sectors does BiovelocITA focus on?
BiovelocITA focuses on Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does BiovelocITA focus on?
BiovelocITA typically invests at the Early stage.
What is BiovelocITA's AUM?
BiovelocITA's assets under management are estimated between $195.6M and $195.6M.